Skip to main content

Table 3 Neurologic outcomes using the GAS scoring system and Barthel scores in all patients with Wilson’s disease during treatment

From: Combined sodium Dimercaptopropanesulfonate and zinc versus D-penicillamine as first-line therapy for neurological Wilson’s disease

  Baseline 2 weeks 4 weeks 8 weeks 1 year
Group 1   N = 93 N = 93 N = 93 N = 93 N = 93
GAS scores 8.74 ± 2.99 8.79 ± 2.90 8.46 ± 3.07 6.79 ± 2.27** 5.89 ± 2.11**
Deterioration (n, %)   7/93 (7.52%) 11/93 (11.8%) 10/93 (10.8%) 8/93 (8.6%)
Improvement (n, %)   9/93 (9.6%) 37/93 (39.8%) 64/93 (68.8%) 82/93 (88.2%)
Barthel scores 54.52 ± 14.20 55.01 ± 14.71 56.99 ± 15.34 66.51 ± 15.51** 74.68 ± 16.15**
Group 2   N = 65 N = 65 N = 65 N = 59 N = 59
GAS scores 8.40 ± 3.49 8.69 ± 3.44 9.20 ± 3.89* 8.17 ± 3.57 7.89 ± 3.76
Deterioration (n, %)   13/65 (20%) 22/65 (33.8%) 21/65 (32.3%) 17/65 (26.2%)
Improvement (n, %)   8/65 (12.30%) 19/65 (29.2%) 30/65 (46.1%) 37/65 (58.5%)
Barthel scores 58.38 ± 18.65 57.08 ± 17.92 53.23 ± 19.27 61.52 ± 18.67 64.57 ± 21.27
  1. Group 1: treated by sodium 2, 3-dimercapto-1-propane sulfonate in combination of zinc; Group 2: treated by D-penicillamine; Global Assessment Scale, GAS Compared with baseline, *P < 0.05, **P < 0.01